Jiangsu Lianhuan Pharmaceutical Co., Ltd. (JIANGSU LIANHUAN PHARMACEUTICAL) Aktie

Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally. The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, milrinone, dapoxetine hydrochloride, tadalafil, and betasine besylate tablets, as well as aprilite, danazol suppositories, and terfenadine tablets. It also provides urinary system drugs, including eprepitant tablets, terazosin tablets, and drotaverine hydrochloride injections; antihistamines comprising ebastine, terfenadine, and cetirizine hydrochloride tablets; cardiovascular drugs that include felodipine, simvastatin, and amlodipine maleate tablets; steroid hormones, which consist of prazosinone sulfate sodium for injection and danazol capsules; and antibiotics, such as oxithromycin capsules. In addition, the company offers API products, such as hydrocortisone, hydrocortisone acetate, levonorgestrel, dexamethasone sodium phosphate, dexamethasone acetate, tazarotene, saxagliptin monohydrate, sacubitril valsartan sodium, phentolamine mesylate, terfenadine, aminomethylbenzoic acid, drotaverine hydrochloride, felodipine, ebastine, lumbrokinase, chloramphenicol, balofoxacin, fludrocortisone acetate, relugolix, hydrocortisone valerate, and bilastine. Further, it engages in the wholesale of chemical raw materials and pharmaceuticals, as well as the sale of medical equipment and electronic products. The company exports its products. Jiangsu Lianhuan Pharmaceutical Co., Ltd. was founded in 1999 and is based in Yangzhou, China.